UCBJF logo

UCBJF UCB S.A.

Other OTC · Biotechnology · Healthcare

$322.09
+2.31 (+0.72%)

UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and pso…

Market Cap: $61.41Bwww.ucb.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
50
2 mentions
—
60d
55
9 mentions
—
90d
61
15 mentions
—
news: 15

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0

Revenue

$4.26B+237.98%
$1.26B$2.26B$3.26B$4.26B
Dec 2006Jun 2026

Analyst Estimates

FY2025
$8.39
$6.36–$10.42
2 analysts
FY2026
$13.15+57% YoY
$12.15–$14.64
1 analysts
FY2027
$14.90+13% YoY
$13.76–$16.58
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jean-Christophe Tellier
Sector
Healthcare
Industry
Biotechnology
Employees
10,117
Beta
0.20
Country
BE
Piotroski score
6 / 9 (Middling)
Altman Z-score
5.25
www.ucb.com